INTRODUCTION
The antiestrogen tamoxifen (TAM) has been the established adjuvant endocrine therapy for postmenopausal women with early breast cancer for close to 30 years. 1 To investigate a potentially superior benefit of estrogen depletion with aromatase inhibitors, large clinical trials have previously presented detailed analyses. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) 2 and BIG 1-98 (Breast International Group 1-98) 3 trials have explored the comparison of TAM monotherapy with the upfront use of aromatase inhibitors (AIs). A recent meta-analysis of these two trials reported a 23% proportional reduction in recurrences with an absolute 3.9% gain at 8 years after starting endocrine treatment. 4 Other trial designs have demonstrated that switching to an additional 3 years of AIs after an initial 2-to 3-year treatment with TAM results in
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similar benefits concerning disease recurrence; some of these trials and meta-analyses of the data have even suggested significant improvements in overall survival (OS) in comparison with 5 years of TAM monotherapy. [4] [5] [6] [7] Among these results, data from 2,262 women randomly assigned in the ABCSG-8 (Austrian Breast and Colorectal Cancer Study Group 8) trial have been reported in a combined analysis with ARNO95 (Arimidex, Nolvadex 95).
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These so-called switching trials and analyses randomly assign and observe patients at the time of potential switch and avoid selective treatment crossover resulting from earlier random assignment at diagnosis. This early random assignment, as in our trial and that of Mouridsen et al, 3 allows unbiased estimation of survival starting at diagnosis but must address substantial bias from women receiving unintended treatment.
To address the question of survival after an endocrine sequence treatment (as opposed to efficacy of switch from TAM to AI), BIG 1-98 compared both monotherapies with two possibilities of sequential endocrine treatment (letrozole followed by TAM and vice versa [four-group option]). The efficacy analyses showed that sequential treatments were not superior to 5 years of letrozole; the average outcomes of a sequence therapy versus letrozole alone did not suggest statistically relevant differences in either direction. This was corroborated by the results of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial.
9
With respect to patients with favorable prognostic factors, the absolute benefit of AI therapy is less established. For example, in the node-negative subgroup of BIG 1-98, neither 5 years of letrozole nor a sequence of letrozole was established to have a significant efficacy advantage over 5 years of TAM. Furthermore, prospective data specifically investigating patients with low-to intermediate-risk treated in the absence of chemotherapeutic agents are scarce. In the Western world, this subgroup accounts for almost 50% of the population with early breast cancer. It is precisely this group of women for whom, with respect to long-term outcome, it is unclear whether optimal use of an AI is up front or after 2 or even 5 years of TAM. Currently, the safety of withholding an AI for 2 to 5 years should be evaluated in light of the on-treatment toxicity and incidence of breast cancer recurrences and deaths.
Here we report the 5-year outcome analysis of ABCSG-8, a prospective evaluation of a well-defined low-to moderate-risk group of endocrine responsive, postmenopausal patients with breast cancer not receiving any other systemic therapy. Both groups of patients were treated with an initial 2 years of TAM and sequenced to anastrozole (ANA) versus TAM for an additional 3 years.
PATIENTS AND METHODS
ABCSG-8 is a prospective, multicenter, randomized, open-label study comparing 5 years of TAM treatment with 2 years of TAM followed by 3 years of ANA. Random assignment occurred immediately after surgery, and no (neo) adjuvant chemotherapy was allowed.
Patients
Patients were postmenopausal women age 80 years or younger with primary, operable, histologically verified, estrogen receptor (ER) -positive and/or progesterone receptor (PgR) -positive, grade 1 or 2 ductal and Gx lobular invasive breast cancer. Additional information concerning the definition of menopausal status, endocrine receptor assessment, surgery, radiotherapy, random assignment, stratification, study treatment, and patient follow-up has been published previously 8 and included in the Appendix (online only). Study recruitment started in January 1996 and ended in June 2004.
Adverse events (AEs) of special interest were predefined in the study protocol and recorded at each study visit. For the purpose of analysis, they were counted once per patient and described with absolute frequencies and percentages (Appendix Table A1 , online only). Serious AEs (SAEs) were stored in the sponsor database and coded according to MedDRA version 12.1 (MSSO, Chantilly, VA; http://meddramsso.com). Events until 60 months are presented. Appendix Table A2 (online only) lists all SAEs on a preferred-term level for this period with either an incidence greater than 1% or a 0.05 difference in relative frequency between treatment arms or statistically significant difference between treatment arms (two-sided P Ͻ .05). Furthermore, slightly deviating from the MedDRA architecture, SAEs were grouped according to event types (Appendix, online only) with clinical relevance to endocrine therapy.
All relevant institutional review boards in Austria approved ABCSG-8. The study was carried out in accordance with the Declaration of Helsinki.
Statistical Analysis
Patients were allocated to treatment using the minimization method according to Pocock et al. 10 After the publication of the combined ABCSG-8/ ARNO95 analysis, 348 patients (9.4%) who had been randomly assigned to 5 years of TAM selectively crossed over to the sequential treatment arm (Fig 1) . In line with a similar publication, all patients selectively changing therapy arm were censored at the time of crossover.
3 These analyses have been termed censored analyses.
Starting in 2004, postmenopausal women with prior 4 to 6 years of endocrine therapy were eligible for extended adjuvant treatment with ANA according to protocol ABCSG-16 (SALSA [Secondary Adjuvant Long-Term Study With Arimidex]; NCT00295620). Although recruitment for ABCSG-16 was finalized at 3,486 patients in June 2010, that trial is still an open trial, with patients receiving active treatment at the time of this analysis; thus, event data from patients enrolled onto that trial must not be used. Another selective censorship of ABCSG-8 patients entering ABCSG-16 after ABCSG-8 would potentially lead to several additional biases. As a result, we decided to limit follow-up of all patients enrolled onto ABCSG-8 up to the time when they entered ABCSG-16 or up to 60 months.
The primary end point of this analysis was recurrence-free survival (RFS) as recently defined in the STEEP system 11 as time from random assignment to the earliest occurrence of local or distant recurrence or death as a result of any cause. Distant relapse-free survival (DRFS; including distant recurrence and death as result of any cause), disease-free survival (DFS; including new contralateral tumors, second primary cancer, local and distant recurrence, and death as result of any cause), and OS were defined exploratory end points. Analyses were performed according to the intention-to-treat (ITT) principle as well as on the basis of the censored population. Median follow-up was calculated by inverse Kaplan-Meier method.
Data are graphically depicted using Kaplan-Meier curves and were tested by log-rank tests. Hazard ratios (HRs) and their corresponding 95% CIs were estimated by Cox proportional hazards regression. Additionally, multivariate Cox regressions were performed using the primary end point of RFS in the censored population to evaluate treatment effect adjusted for known prognostic factors such as nodal status, age, hormone receptor expression, and tumor stage. Interaction between treatment and prognostic factors were tested using RFS in the censored population, adjusting for remaining prognostic factors. Toxicity evaluation is included in the Appendix, (online only). All analyses were calculated using SAS version 9.1 (SAS Institute, Cary, NC).
Role of the Funding Source
The study protocol was developed and written by R.J. and M.G. The trial was managed by ABCSG. Funding and organizational support was provided by the trial sponsor AstraZeneca. ABCSG statisticians and investigators carried out all data analyses independent of the sponsor.
RESULTS
Trial Profile
This trial included 3,714 postmenopausal patients for random assignment. Cohorts, treatment allocation, follow-up, and analyses are depicted in Figure 1 . Data from 348 women (9.4%) were censored at the time of crossover for the censored analyses. This included 341 women (18%) from the TAM arm. All follow-up was censored at either 60 months or at the time of random assignment in ABCSG-16 for both the ITT and censored analyses. As a consequence, median follow-up in this analysis is 60 months, with a range of 0.5 to 60 months (mean follow-up: ITT analysis, 57.8 months; censored analysis, 55.5 months). Follow-up included 17,563 woman-years (8,709 in TAM arm; 8,853 in sequence arm).
Patient Characteristics
The treatment groups were well balanced in terms of all clinical and therapeutic parameters assessed (Table 1) . Median age at the time of surgery was 63.8 years; 74.6% of patients were node negative, and 74.9% had tumors smaller than 2 cm. A high expression of ER (ERϩϩϩ) was found in 61.9% of patients, and 58.1% showed a combined expression of ERϩϩ and PgRϩϩ or higher. ERnegative, PgR-positive tumors were found in 1.2% of patients (46 patients; 23 in each arm); 75.7% had G2 tumors, and 19.9% had G1. Breast conservation was achieved in 82% of patients, and 70.4% received radiotherapy.
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Efficacy
Women assigned to the sequence of TAM followed by ANA showed a decrease of 20.0% (ITT: HR, 0.80; 95% CI 0.63 to 1.01; P ϭ .06) in risk of recurrence (124 v 152 events; Fig 2A) . This was a In addition to RFS, Figure 3 depicts HRs and 95% CIs for the exploratory efficacy end points of DFS, DRFS, and OS and provides a better understanding of which types of events drive the efficacy of study arms. In addition to recurrences and deaths, the calculation of DFS included both secondary malignomas and contralateral breast cancer. ITT analysis did not indicate a benefit concerning this end point (HR, 0.91; 95% CI, 0.75 to 1.10; P ϭ .33). There was no statistically significant difference between study arms concerning overall survival (ITT: HR 0.87; 95% CI, 0.65 to 1.16; P ϭ .34). However, the observed difference in recurrence did not seem to come from a reduction in local recurrence, because DRFS revealed a 22% reduction in risk in favor of ANA (ITT: HR, 0.78; 95% CI, 0.60 to 0.99; P Ͻ .05).
Both RFS and DRFS are depicted in Kaplan-Meier prevalence curves from the ITT analyses (Figs 2A, 2B) . At 60 months of follow-up, 139 DRFS versus 110 DRFS events translate to an absolute difference of 1.6%. In terms of RFS, an absolute 1.6% difference in 60-month survival rates in favor of ANA has been recorded (152 v 124 events) .
A descriptive analysis of all first events (ITT analysis) is provided in Table 2 . There was a low rate of locoregional (n ϭ 36) and contralateral (n ϭ 29) recurrences, with no difference between treatment arms. Distant recurrences and secondary malignant conditions each accounted for approximately one third of all first events, and deaths without previous recurrence comprised 21.3% of all events. There were fewer distant recurrences in the ANA arm (n ϭ 72 v n ϭ 57) and fewer deaths recorded for the sequence strategy; 49.2% (n ϭ 87) of all deaths were recorded without prior recurrence of breast cancer; 47 of these deaths occurred in the TAM arm, and 39 occurred in the ANA arm. In summary, at 60 months of follow-up, the group difference of the RFS primary end point did not reach statistical significance. However, exploratory analyses of distant metastases indicated a clinically meaningful benefit concerning the anticancer efficacy of the sequence strategy.
Multivariate Analyses and HRs in Subgroups
To further explore the effect of sequential ANA treatment on the risk of recurrence, treatment was evaluated in combination with known prognostic factors (Table 3) . Clearly, age older than 60 years, positive nodal status, and increasing tumor size were demonstrated to increase risk of recurrence. High expression of both ER and PgR decreased risk of recurrence by 20% in multivariate analysis. Finally, treatment with ANA was associated with a significant 22% decrease in risk. There were no significant interactions between any of the covariates and the type of treatment allocated. The treatment effect of TAM followed by ANA was similar in subgroups determined by baseline characteristics of the study population (Appendix Fig A1, online only).
Safety and Toxicity
Approximately 70% of all patients experienced hot flushes, and one third of patients suffered from vaginal bleeding or discharge at least once during the study period. Both of these AEs were equally distributed. There was a moderate, statistically significant difference with 29.3% of patients experiencing bone pain in the TAM arm versus 32.9% in the sequence arm (P Ͻ .02). There were no differences concerning asthenia, hair loss, allergy/skin toxicity, nausea, and diarrhea between treatment arms (Appendix Table A1 , online only).
Selected MedRA databank-coded SAE preferred terms are listed in Appendix Table A2 (online only) . Furthermore, SAEs were grouped according to categories frequently associated with antihormonal treatment (Appendix Table A3 , online only). Fracture was a rare event, with a moderately lower rate in the TAM arm not reaching statistical significance (1.5% v 2.3%; P Ͻ .08). By far the most common SAEs recorded were events summarized as uterine disorders (n ϭ 636); 20.2% of women in the TAM arm experienced this type of SAE, as opposed to 14.1% in the sequence arm (P Ͻ .001). The vast majority of these SAEs originated from reports of uterine polyps and endometrial hyperplasia (Appendix Table A2 , online only). Musculoskeletal disorders were significantly less frequent (2.8% v 4.1%; P Ͻ .03) in the TAM arm. There were no significant differences detected in SAEs grouped as cardiovascular or thromboembolic.
DISCUSSION
ABCSG-8 is a large phase III trial evaluating adjuvant endocrine therapy in the setting of postmenopausal, hormone receptor-positive early breast cancer. The aim of this study was to compare the efficacy and toxicity of an additional 3 years of ANA versus an additional 3 years of TAM, after a common 2 years of TAM treatment in both arms. To our knowledge, this trial, together with part of the four-arm option of BIG 1-98, is the only large phase III trial exploring the sequential therapy of an AI with TAM monotherapy. A comparison of patient characteristics of ABCSG-8 with those of similar endocrine treatment trials 2, 12, 14, 15 clearly shows a patient population with low-to intermediate-risk factors for recurrence; close to 75% of patients were node negative and had tumors smaller than 2 cm. In addition, ABCSG-8 excluded women with G3 tumors and did not allow adjuvant chemotherapy. ABCSG-8 shows the highest survival rates at 5 years of follow-up in comparison with BIG 1-98 or the ATAC trial, for example. We recorded a 5-year DFS of 89.5% in the sequence arm and 88.5% in the monotherapy arm (data not shown; DFS exploratory end point in ABCSG-8). These results confirm both the estimate of risk based on simple prognostic criteria and add to the clinical evidence indicating that these subgroups can be spared cytotoxic treatment.
The primary end point of this study shows a nonsignificant 20% reduction in recurrence risk. The small efficacy benefits observed were driven by a lower number of distant metastases and deaths. Patients were randomly assigned at diagnosis. Our study and BIG 1-98 have shown substantial treatment crossover after 2 years of TAM. Random assignment after 2 years with prospective registration at diagnosis would have prevented this study limitation.
Furthermore, because of the identical treatment with TAM for 2 years, the assumption of proportional hazards is not satisfied by definition if all 5 years are included in the analysis. An alternative analysis strategy that would have estimated treatment effects in years 3 to 5 might have shown even larger treatment effects of ANA. Despite these limitations, it seems prudent to identify locoregional and contralateral events as extremely rare events in both arms and describe the observed reduction in distant recurrences as clinically meaningful to disease control.
Are there alternative motives, other than individually occurring toxicities, to treat postmenopausal women with a TAM-ANA sequence? Women with ER-positive disease, particularly, have been shown to remain at sustained risk of relapse up to 15 years after diagnosis despite favorable prognostic factors. 16 In line with this finding, excellent efficiency has been demonstrated with extended treatment with an AI after 5 years of TAM, especially in node-positive women. 17, 18 This widening of focus from early recurrence of disease to a 15-to 20-year time span of possible recurrence may provide a renewed rationale for sequences including TAM. For a postmenopausal woman diagnosed with ER-positive breast cancer, it is currently not clear whether an AI would optimally benefit her long-term survival when used up front, after 2 years of TAM, or after 5 years of TAM.
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Predictive factors of patients most likely to benefit from an AI, or at least the best possible definition of patient risk, are a common goal in breast cancer research. ABCSG has carried out translational work evaluating a gene expression signature. In that study, 20 we validated that the molecular predictor is able to improve the prediction of distant metastases otherwise estimated by clinicopathologic factors. Furthermore, we 21 and others 22 have investigated host-related factors such as body mass index to predict AI benefit. In addition, pharmacogenomic tools to predict the individual metabolism of TAM may be of particular interest.
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This study did not yield clear differences concerning AEs commonly associated with endocrine therapy. This fairly even distribution of AEs experienced should be attributed to the following: one, a spectrum of adverse effects that is largely overlapping between TAM and ANA; and two, the identical 2-year initial TAM treatment in both arms. However, the continued treatment with TAM led to a significant increase of uterine disorders reported as SAEs most likely resulting from surgical interventions such as curettage. This analysis reports on-treatment SAEs and finds a clear one-third increase in endometrial hyperplasia and polyps. To some degree, this most likely reflects the Austrian guidelines concerning the indications for curettage at the time, 24 but nevertheless, these data represent a serious concern when prescribing TAM.
In summary, ABCSG-8 provides prospective data about the sequence of TAM-ANA in comparison with 5 years of TAM therapy in a large, low-to intermediate-risk cohort treated without chemotherapy. On average, the inclusion of ANA in the first 5 years of endocrine therapy leads to small improvements in breast cancer recurrence and on-treatment toxicity. These data support the sequential use of ANA in women considered to have a favorable prognosis. 
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